Association between CDKN1A Ser31Arg and C20T gene polymorphisms and colorectal cancer risk and prognosis

In Vivo

Volumn 24, Issue 2, 2010, Pages 179-183

  Cacina, Canan ^a   Yaylim Eraltan, Ilhan ^a   Arikan, Soykan ^b   Saglam, Esra Kaytan ^c   Zeybek, Umit ^a   Isbir, Turgay ^a,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b SB Istanbul Education and Research Hospital   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

Author keywords

CDKN1A; Cell cycle; Polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GENOMIC DNA; SERINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC);

EID: 77950604195     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fujiwara T, Stolker JM, Watanabe T, Rashid A, Longo P, Eshleman JR, Booker S, Lynch HT, Jass JR, Green JS, Kim H, Jen J, Vogelstein B and Hamilton SR: Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 153: 1063-1078, 1998. (Pubitemid 28465830)
2. Hao XP, Du MQ, Bishop AE and Talbot IC: Imbalance between proliferation and apoptosis in the development of colorectal carcinoma. Virchows Arch 433: 523-527, 1998. (Pubitemid 28561184)
3. Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedullà F and Alama A: Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 5: 1837-1842, 1999.
4. Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K and O'Brien TJ: Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 6: 102-108, 1999. (Pubitemid 29160204)
5. Cordon-Cardo C: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995.
6. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
7. MacLachlan TK, Sang N and Giordano A: Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5: 127-156, 1995.
8. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993. (Pubitemid 24036020)
9. Lee MH, Reynisdottir I and Massague J: Cloning of p57/KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-649, 1995.
10. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini, A, Harper JW and Elledge SJ: p57/KIP2, a structurally distinct member of the p21/CIP1 Cdk inhibitor family is a candidate tumor suppressor gene. Genes Dev 9: 650-662, 1995.
11. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin DM, Mercer WE, Kinzler KW and Vogelstein B: WAFl, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
12. 1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
13. 2 arrest after DNA damage. Science 282: 1497-1501, 1998. (Pubitemid 28538613)
14. Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 79: 2424-2429, 1997. (Pubitemid 27251028)
15. Lukas J, Groshen S, Saffari B, Niu N, Reles A, Wen WH, Felix J, Jones LA, Hall FL and Press MF: WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 150: 167-175, 1997. (Pubitemid 27027107)
16. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB and Andrulis IL: Two variants of the CIP/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4: 1089-1092, 1995.
17. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J and Goodfellow PJ: CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 63(9): 2033-2036, 2003. (Pubitemid 36538603)
18. Rodrigues FC, Kawasaki-Oyama RS, Fo JF, Ukuyama EE, Antonio JR, Bozola AR, Romeiro JG, Rahal P and Tajara EH: Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? Cancer Genet Cytogenet 142: 92-98, 2003.
19. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G and Beckman G: Association between the p21 codon 31 A1(Arg) allele and lung cancer. Hum Hered 46: 221-225, 1996. (Pubitemid 26185333)
20. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K and Wake N: WAF1 genotype and endometrial cancer susceptibility. Gynecol Oncol 72: 187-192, 1999. (Pubitemid 29093773)
21. WAF1/CIP1 polymorphism in human ovarian cancer. Int J Oncol 15: 117-119, 1999.
22. Miller SA, Dykes DD and Polesky HF: A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3): 1215, 1988.
23. Ressiniotis T, Griffiths GP, Keers MF, Chinnery PA and Birch M: A polymorphism at codon 31 of gene p21 is not associated with primary open angle glaucoma in Caucasians. BMC Ophthalmology 5: 5, 2005. (Pubitemid 40746219)
24. Ma H, Jin G, Hu Z, Zhai X, Chen W, Wang S, Wabg X, Qin J, Gao J, Liu J, Wang X, Wei Q and Shen H: Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int J Cancer 119: 2173-2178, 2006. (Pubitemid 44423677)
25. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B and Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781-3784, 1994.
26. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ and Fontana JA: p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 74: 529-534, 1997. (Pubitemid 27486511)
27. Pruneri G, Pignatoro L, Carboni N, Bufa R, Di Finizio D, Cesana BM and Neri A: Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in larygeal cancer. J Clin Oncol 17: 3150-3159, 1999. (Pubitemid 29470645)
28. Birgander R, Sjalander A, Saha N, Spitsyn V, Beckman L and Beckman G: The codon 31 polymorphisn of the p53-inducible gene p21 shows distict differences between major ethnic groups. Hum Hered 46: 148-154, 1996. (Pubitemid 26110386)
29. Kesheva C, Frye BL, Wolff MS, McCanlies EC and Weston A: Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev 11: 127-130, 2002. (Pubitemid 34118322)
30. Chedid M, Michieli P, Lengel C, Huppi K and Givol D: A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF/CIP1. Oncogene 9: 3021-3024, 1994. (Pubitemid 24296780)
31. Li YJ, Laurent-Puig P, Salmon RJ, Thomas G and Hamelin R: Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10: 599-601, 1995.
32. Comings DE and MacMurray JP: Molecular heterosis: a review. Mol Genet Metab 71: 19-31, 2000.